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ABSTRACT
Using electrophoresis and replication mapping,
we show that the presence of DNA adducts of
bifunctional antitumor cisplatin or monodentate
[PtCl(dien)]Cl (dien=diethylenetriamine) in the sub-
strate DNA inhibits eukaryotic topoisomerase 1
(top1) action, the adducts of cisplatin being more
effective. The presence of camptothecin in the sam-
ples of platinated DNA markedly enhances effects of
Pt–DNA adducts on top1 activity. Interestingly, the
effects of Pt–DNA adducts on the catalytic activity of
top1 in the presence of camptothecin differ depend-
ing on the sequence context. A multiple metallation
of the short nucleotide sequences on the scissile
strand, immediately downstream of the cleavage
site impedes the cleavage by top1. On the other
hand, DNA cleavage by top1 at some cleavage
sites which were not platinated in their close prox-
imity is notably enhanced as a consequence of
global platination of DNA. We suggest that this
enhancement of DNA cleavage by top1 may consist
in its inability to bind to other cleavage sites plati-
nated in their close neighborhood; thus, more mole-
cules of top1 may become available for cleavage at
the sites where top1 normally cleaves and where
platination does not interfere.
INTRODUCTION
Platinum-based drugs such as cisplatin, carboplatin, oxa-
liplatin and nedaplatin are clinically used against various
solid tumors including genitourinary, colorectal and non-
small cell lung cancers (1). The clinical use of antitumor
platinum drugs, however, is restricted since many tumor
cells display inherent or acquired resistance to platinum-
based drugs, other limitations are due to dose-limiting
side eﬀects (2). Continuous eﬀorts have been made to
overcome these limitations with a primary focus on the
development of new platinum drugs. Designing new anti-
tumor platinum drugs depends on understanding details
of molecular and biochemical mechanisms associated
with the biological eﬀects of the existing platinum
agents. Therefore, studies focused on understanding com-
plex mechanisms underlying antitumor activity of plati-
num drugs represent now very active research area. It is
generally accepted that the main biological event that trig-
gers the anticancer properties of the platinum drugs is
formation of platinum–DNA adducts (2–4).
Studies focused on mechanisms of antitumor activity
of cisplatin have revealed an interesting phenomenon
demonstrating that the frequency of the individual
adducts formed on DNA by antitumor platinum com-
pounds (which may diﬀer in their biological eﬀects) is
dependent on DNA topology (5,6). These observations
insinuate hypothesis that the mechanism of biological
activity of platinum drugs could be also aﬀected by cata-
lytic eﬃciency of topoisomerases.
Topoisomerases are ubiquitous and vital enzymes
because of their role in the control of the topological
state of DNA. As they alter the topology of DNA, topo-
isomerases participate in nearly all events related to DNA
metabolism including replication, transcription and
recombination. The topoisomerases are now viewed as
important therapeutic targets for cancer therapy; in parti-
cular, topoisomerase inhibitors are considered promising
anticancer agents (7–9). Hence, it is somewhat surprising
that the information on the nature of direct eﬀects
of cisplatin on topoisomerase catalytic activity is
relatively rare.
Cisplatin inhibits topoisomerase II leading to a tran-
sient alteration of DNA supercoiling (10). In vitro studies
of the eﬀect of cisplatin on the supercoiling activity of
puriﬁed topoisomerase II have revealed that cisplatin
is an eﬃcient inhibitor of this enzyme as a consequence
of a direct interaction of cisplatin with the enzyme.
On the other hand, the results of several reports (11,12)
are consistent with the hypothesis that topoisomerase
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platin. For instance, a synergism between cisplatin, oxali-
platin or nedaplatin and several topoisomerase I (top1)
inhibitors in inhibiting its catalytic activity has been
demonstrated in vitro (11,13) and in human small cell
lung cancer cells (13–16). It is reasonable to assume that
severe conformational alterations induced in DNA by the
crosslinks of cisplatin and its analogs modulate the stabi-
lization of top1-drug-DNA cleavable complexes and/or as
topoisomerase inhibitors may inhibit repair of cisplatin
adducts (12,14) so that the antitumor activity of the plat-
inum drug is enhanced. Also interestingly, the reaction of
closed circular DNA containing cisplatin adducts with
top1 yields unique topoisomers (17). In addition, it has
been shown (18) that 1,3-GTG intrastrand crosslinks
[which represent only very minor DNA adducts of cis-
platin (19)] formed by this metallodrug in 24-bp
oligonucleotide containing no preferential recognition
site of top1, enhance DNA cleavage by top1 in the pres-
ence of top1 poison such as camptothecin (CPT). Hence,
further investigations of the eﬀect of DNA adducts
of platinum compounds on the catalytic activity of topo-
isomerases are warranted to deﬁne their role in the mech-
anism of the cytotoxicity of these metallodrugs.
The purpose of this work is to determine whether
activity of eukaryotic top1 is aﬀected by the modiﬁcation
of DNA by antitumor cisplatin. Positive results may rep-
resent a new alternative concept for the mechanism, eﬀec-
tive in some types of tumors, underlying antitumor
activity of transition metal-based drugs. We selected two
complexes to investigate the eﬀects of platinum adducts
formed in DNA on the activity of top1; bifunctional
cisplatin (Figure 1A) and ineﬀective monodentate
[PtCl(dien)]Cl (dien=diethylenetriamine) (Figure 1B) fre-
quently used in the studies of structure–pharmacological
activity relationship of platinum compounds (20).
Bidentate cisplatin forms on the DNA major intrastrand
adducts between two adjacent purine residues ( 90%),
mainly such as 1,2-GG intrastrand crosslinks of adjacent
deoxyriboguanosines with platinum binding the N7 posi-
tions of bases. These crosslinks are believed to be at
the origin of antitumor activity of cisplatin and its analogs
(1–4). It has been demonstrated that formation of 1,2-GG
intrastrand crosslink by cisplatin leads to marked con-
formational alterations in DNA structure including
unwinding the DNA duplex in the vicinity of the site of
platination, bending it toward the major groove and gen-
erating a widened and shallow minor groove (2). Owing to
the fact that top1 binds speciﬁcally to the sites in DNA
that contain a number of preferential binding sites of cis-
platin and its analogs (21–23) it seems reasonable to
expect that such a severe distortion of DNA or just metal-
lation per se within top1 DNA binding site aﬀects activity
of this enzyme. On the other hand, [PtCl(dien)]Cl forms in
DNA monofunctional adducts which induce only minor
changes in DNA structure so that it is of interest to com-
pare the eﬀects of cisplatin adducts on activity of top1
with those of less distorting adducts of [PtCl(dien)]Cl.
MATERIALS AND METHODS
Starting materials
Plasmid pSP73KB [2455bp, supercoiled density
s= 0.063] was isolated according to standard proce-
dures. Phagemid pBluescript SK( ) (2958bp,
s= 0.058) was purchased from Stratagene (La Jolla,
CA, USA). PvuII and HindIII restriction endonucleases,
T4 polynucleotide kinase and Circum Vent
TM Thermal
Cycle Sequencing Kit with Vent(exo
 ) DNA polymerase
were purchased from New England Biolabs (Beverly, MA,
USA). The 161-bp DNA fragment was prepared by digest-
ing supercoiled pBluescript SK( ) phagemid with
PvuII and HindIII restriction endonucleases in the NEB
buﬀer 2 supplied by the manufacturer and separated
by electrophoresis in a 1% agarose gel made in 1  TBE
buﬀer. The 161-bp fragment was isolated from the gel by
Promega Wizard SV Gel clean-up system. Approximately
100ng of the fragment was 30-end-labeled at the HindIII
site by ﬁll-in reaction with [a-
32P]-dATP and 0.5mM
dGTP, dCTP and dTTP, in the EcoPol buﬀer supplied
by the manufacturer with 1 unit of the Klenow fragment
from DNA polymerase I (exonuclease minus, mutated
to remove the 30–50 proofreading domain) (KF
 ).
Unincorporated [a-
32P]-dATP was removed by Promega
Wizard SV Gel clean-up system, and the eluate containing
the 30-end-labeled 161-bp fragment was collected, freeze
dried and redissolved in 40ml of 10mM Tris–HCl, pH
7.4. The synthetic oligodeoxyribonucleotides were pur-
chased from DNA Technology A/S (Arhus, Denmark).
The DNA top1 from calf thymus, KF
  and bovine
serum albumin (BSA) were purchased from Takara Bio
Inc. (Otsu, Shiga, Japan). [a-
32P]-dATP and [g-
32P]-ATP
were from MP Biomedicals, LLC (Irvine, CA, USA).
Acrylamide, bis(acrylamide) and ethidium bromide
(EtBr) were from Merck KgaA (Darmstadt, Germany).
Agarose was from FMC BioProducts (Rockland, ME,
USA). Wizard SV Gel and PCR Clean-Up System used
to extract and purify 161-bp DNA fragment (vide infra)
were purchased from Promega (Madison, WI, USA).
CPT, NaCN, dimethyl sulfoxide (DMSO), dimethyl sul-
fate (DMS) and cisplatin were from Sigma-Aldrich
(Prague, Czech Republic). SDS was from Serva
(Heidelberg, Germany). CPT was dissolved in DMSO at
10mM concentration and stored at –208C. [PtCl(dien)]Cl
was a kind gift of Prof. G. Natile from University of Bari.
Platination reactions
Plasmid DNA or the 161-bp fragment were incubated with
the platinum complex in 10mM NaClO4 at 378C for 24h
Figure 1. Chemical structures of cisplatin (A) and [PtCl(dien)]Cl (B).
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cules of the platinum compound bound (coordinated) per
nucleotide residue (rb value) was determined by ﬂameless
atomic absorption spectrophotometry (FAAS). It was
veriﬁed that under these conditions of DNA platination,
no free molecules of the platinum complex remained in
the samples further used in the experiments described in
this work.
The oligonucleotides were allowed to react with the
platinum compounds, and repuriﬁed as described pre-
viously (24,25). The single-stranded oligonucleotide (the
top strand in Figure 6A) was reacted in stoichiometric
amounts with cisplatin or [PtCl(dien)]Cl. The platinated
oligonucleotides were puriﬁed by FPLC. It was veriﬁed by
platinum FAAS and by the measurements of the optical
density that the modiﬁed oligonucleotides contained one
platinum atom. It was also veriﬁed using DMS footprint-
ing of platinum on DNA (25,26) that in the platinated top
strands the N7 position of both neighboring guanines for
cisplatin or one of the guanine residues at +1 or +2 posi-
tion for [PtCl(dien)]Cl was not accessible for reaction with
DMS. Brieﬂy, platinated and nonmodiﬁed top strands
(50-end-labeled with
32P) were reacted with DMS. DMS
methylates the N7 position of guanine residues in DNA
producing alkali labile sites (27). However, if N7 is cova-
lently bound to platinum, it cannot be methylated. The
oligonucleotides were then treated with hot piperidine
and analyzed by denaturing polyacrylamide (PAA) gel
electrophoresis. For the nonmodiﬁed oligonucleotides,
shortened fragments due to the cleavage of the strand at
the two methylated guanine residues were observed in the
gel. However, no such bands were detected for the plati-
nated oligonucleotides. These results indicate that one cis-
platin or [PtCl(dien)]Cl molecule was coordinated to both
or one of the neighboring guanine residues, forming the
1,2-GG intrastrand crosslink or monofunctional adduct.
FPLC puriﬁcation was carried out on a Pharmacia
Biotech FPLC System with MonoQ 5/50 GL.
Thus, all experiments described in the present work
were performed in the absence of free (unbound) platinum
complex present in the reaction mixtures containing top1.
In this way, any inhibition of top1 catalytic activity due to
a direct modiﬁcation of top1 by the platinum complexes
was excluded.
Top1-catalyzed relaxation of negatively supercoiled DNA
Each reaction mixture (40ml, total volume) contained 2mg
of supercoiled pSP73(KB) plasmid DNA nonmodiﬁed or
globally modiﬁed by cisplatin or [PtCl(dien)]Cl in 35mM
Tris–HCl, pH 8.0, 72mM KCl, 5mM MgCl2, 5mM DTT,
5mM spermidine, 0.01% BSA and  4pM top 1. Some
reaction mixtures contained 100mM CPT. The order of
addition was DNA, buﬀer, CPT and top 1. The reaction
mixtures were incubated at 378C, and at indicated times
9ml aliquots were withdrawn and the reaction terminated
by the addition of 0.5ml of 10% SDS. All samples were
then mixed with the loading buﬀer and loaded onto a
1% agarose gel running at 258C in the dark with TAE
(Tris–acetate/EDTA) buﬀer and the voltage set at 25V.
The gels were then stained with EtBr, followed by
photography with transilluminator. The bands were quan-
titated by integration with the AIDA image analyzer soft-
ware (Raytest, Germany). Plasmid DNA relaxation
mediated by top1 was determined by quantitating the
loss of supercoiled plasmid DNA having original super-
coiled density s= 0.063 as a function of time. It was
veriﬁed that under the conditions employed, the band
intensity in the negative of the gel photograph was directly
proportional to the amount of DNA present.
Top1-mediated cleavage of the 161-bp DNA fragment
Aliquots of the 161-bp fragment [PvuII/HindIII fragment
of pBluescript SK( ) phagemid] were modiﬁed by cispla-
tin or [PtCl(dien)]Cl to various values of rb and then
allowed to react with top1 at 208C for 30min in the
absence or presence of surplus of CPT. Each reaction
(5ml) contained top1 at the concentration of  50pM,
the 161-bp fragment at the concentration of  1.5nM
and CPT at the concentration of 5mM. Reactions were
terminated by adding SDS (0.5% ﬁnal concentration)
and each sample was divided into two halves. One half
was mixed with formamide loading buﬀer and analyzed
on 13% PAA/7M urea denaturing gel. The other half was
incubated with 0.3M NaCN (pH 11) at 458C for 10h in
the dark to remove platinum complexes from DNA.
Samples were then precipitated by ethanol, redissolved
in formamide loading buﬀer and analyzed on a denaturing
PAA gel. The autoradiograms were visualized and quan-
tiﬁed by using the bio-imaging analyzer.
Sequence preference of Pt-DNA adducts in the 161-bp
DNA fragment
The primer extension assay was used to evaluate the
sequence selectivity of DNA modiﬁcation by cisplatin
and [PtCl(dien)]Cl. The 161-bp fragment [from
pBluescript SK( ) phagemid, vide supra] was incubated
with platinum complexes in 10mM NaClO4 for 24h at
378C to obtain rb=0.005 or 0.008. The excess of drug
was removed by ethanol precipitation. Circum Vent
TM
Thermal Cycle Sequencing Kit with Vent(exo
 ) DNA
polymerase was used along with the protocol for thermal
cycle DNA sequencing recommended by the manufacturer
with small modiﬁcations (28) with 50-end-labeled 18-mer
primers (50-CTGGCGAAAGGGGGATGT complemen-
tary to the sites 1–18 in the bottom strand and 50-TATC
GATACCGTCGACCT complementary to the sites
140–157 in the top strand of the 161-bp fragment). The
synthesis products were separated by electrophoresis on
a denaturing PAA gel (6% PAA/8M urea); sequence lad-
ders were obtained in parallel using untreated control
DNA fragment.
Top1-mediated cleavage of the 30-bp oligonucleotide
duplex
The upper strand of the duplex (its sequence is shown in
Figure 6A) unplatinated or containing single, site-speciﬁc
platinum adduct was annealed with unplatinated com-
plementary strand (the bottom strand of the duplex
shown in Figure 6A) in 50mM NaCl, 10mM Tris–HCl
with 0.1mM EDTA (pH 7.4) and 30-end-labeled with
5434 Nucleic Acids Research, 2009, Vol. 37,No. 16[a-
32P]-dATP and KF
 . Unincorporated [a-
32P]-dATP
was removed by G50 Sephadex column. Each reaction
(5ml) contained DNA substrates ( 5nM) which were
incubated with  60pM top1 for 30min at 208C in the
presence or absence of 10mM CPT in 10mM Tris–HCl,
pH 7.5, 50mM KCl, 5mM MgCl2, 0.1mM EDTA and
15mg/ml BSA. Reactions were stopped by addition of
0.5% SDS, mixed with formamide loading buﬀer and ana-
lyzed on a 24% PAA/7M urea denaturing gel.
Other physical methods
Absorption spectra were measured with a Beckman DU
7400 spectrophotometer equipped with a thermoelectri-
cally controlled cell holder and quartz cells with the path
length of 1cm. The FAAS measurements were carried out
on a Varian AA240Z Zeeman atomic absorption spec-
trometer equipped with a GTA 120 graphite tube atomi-
zer. For FAAS analysis, DNA was precipitated
with ethanol and dissolved in 0.1M HCl. The gels were
visualized by using a BAS 2500 FUJIFILM bioimaging
analyzer, and the radioactivity associated with bands was
quantitated with the AIDA image analyzer software
(Raytest, Germany).
RESULTS
Inhibition of top1-mediated DNA relaxation
A DNA relaxation assay was utilized to examine the
eﬀects of damage induced in the substrate by adducts of
platinum complexes on the catalytic activity of eukaryotic
DNA top1 and how CPT aﬀects top1–DNA interactions
under such conditions. This assay measured the conver-
sion of naturally negatively supercoiled pSP73KB plasmid
into relaxed covalently closed circular DNA. The eﬀect of
DNA platination on top1 catalyzed DNA relaxation was
assessed by comparing the rate of relaxation of unplati-
nated supercoiled plasmid with plasmid globally modiﬁed
by bidentate cisplatin (Figure 2A) or monodentate
[PtCl(dien)]Cl (Figure 2B) in the absence or presence of
CPT. The level of platination of DNA could not be too
high because both platinum complexes, cisplatin in partic-
ular, unwind the DNA (29), which may complicate ana-
lysis of the bands in gels at higher levels of platination.
The highest rb value used was 0.02 or 0.04 in the case of
cisplatin or [PtCl(dien)]Cl, respectively. The time course
of relaxation of plasmid DNA modiﬁed by cisplatin
or [PtCl(dien)]Cl by top1 in the presence and absence
of CPT is shown in Figure 2C–E. Modiﬁcation of DNA
by either complex reduced the rate at which top1 relaxed
supercoiled form of DNA. Cisplatin is more eﬃcient than
[PtCl(dien)]Cl at rb=0.02, nevertheless after  20min the
intensities of the bands corresponding to supercoiled
DNA were in both cases reduced to zero. Comparison
of the plots shown in Figure 2D and E reveals that the
rate of relaxation of DNA by top1 decreases with growing
level of DNA platination.
CPT and its derivatives belong to eﬃcient inhibitors
of top1 catalytic acitivity which have recently been intro-
duced in cancer treatment. CPT inhibits the religation
step. When CPT was present in the samples containing
DNA modiﬁed by the platinum complexes, resulting
inhibitory eﬀects on top1 activity were rather additive
than synergistic (Figure 2). Interestingly, some more
than additive eﬀects as regards the inhibition of top1
activity of CPT and platinum adducts are observed at
the longest times of the reaction (24min) when inhibition
caused by platination in the absence of CPT is nearly zero.
Top1-mediated cleavage of 161-bp DNA fragment
Top1 cleaves DNA at multiple sites, but selectively at
certain nucleotide sequences (21–23,30). Thus, the other
way to determine top1 catalytic activity involves an ana-
lysis of the DNA cleavage pattern. We examined inﬂuence
of DNA adducts of cisplatin or [PtCl(dien)]Cl on top1-
mediated cleavage in the 161-bp 30-end-labeled PvuII/
HindIII fragment of pBluescript SK( ) phagemid DNA.
This fragment contains several sequences corresponding
to top1 speciﬁc and preferential recognition sites (31).
First, we examined the cleavage in the absence of CPT,
but top1 did not produce detectable cleavage although an
amount of top1 considerably higher than in the DNA
relaxation assay was used (data not shown). Thus, CPT
was required for observing the expected 161-bp duplex
cleavage products (Figure 3, lanes, control) so that we
examined eﬀect of DNA adducts of the platinum com-
plexes on top1-mediated cleavage in the presence of
CPT. CPT has been shown to stimulate DNA cleavage
by top1 at its recognition sequences although it enhances
cleavage at some sites much more than at others.
Moreover, it does not alter signiﬁcantly the sequence spe-
ciﬁcity of enzyme-mediated cleavage (30). The sites of
top1-mediated single-strand cleavage produced by CPT
on a 161-bp fragment are shown in Figure 3 (lanes con-
trol). Five major sites of cleavage can be clearly seen; the
sequences at which the major cleavage occurs are dis-
played on the right side of the Figure 3B. The guanines
as preferential binding sites of cisplatin and [PtCl(dien)]Cl
are highlighted as bold letters. An examination of the gels
reveals that with growing level of the modiﬁcation of the
fragment by cisplatin (Figure 3A) or [PtCl(dien)]Cl
(Figure 3B), cleavage induced by CPT was aﬀected at
some cleavage sites as evident from changes of intensities
of some bands corresponding to the cleavage fragments.
Figure 4 demonstrates the dependence of the DNA cleav-
age mediated by top1 in the presence of CPT on the extent
of modiﬁcation of the DNA by cisplatin (Figure 3A) or
[PtCl(dien)]Cl (Figure 3B). DNA cleavage at the sites in
the 37 and 119 positions was strongly suppressed with
growing global modiﬁcation of the fragment by both cis-
platin and [PtCl(dien)]Cl, cisplatin being more eﬀective
(Figure 4). On the other hand, DNA cleavage at the
sites corresponding to the 92 and 97 positions was notably
enhanced in particular at lower levels of modiﬁcation by
[PtCl(dien)]Cl and cisplatin, respectively. The cleavage of
the 161-bp fragment modiﬁed by cisplatin was not aﬀected
or was aﬀected weakly at the sites corresponding to the 70
and 92 positions, respectively; when the fragment was
modiﬁed by [PtCl(dien)]Cl the cleavage was unaﬀected
or aﬀected weakly at the sites corresponding to 70 and
97 positions.
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DNA fragment
This procedure involved the extension by VentR(exo )
DNA polymerase at the 30-end of the primer up to the
metal adduct on the template strand of PvuII/HindIII
fragment of pBluescript SK( ) phagemid DNA. The
products of the synthesis were then examined on DNA
sequencing gels, and the sequence speciﬁcity of the plati-
num adduct formation was determined to the exact
nucleotide. In vitro DNA synthesis on DNA templates
containing the adducts of cisplatin or [PtCl(dien)]Cl gen-
erated a population of DNA fragments, indicating that
the adducts of these complexes terminate DNA synthesis
(Figure 5A, lanes cisPt1,2 and dienPt1,2). In general,
intensity of the bands corresponding to the termination
of DNA synthesis due to the adducts of [PtCl(dien)]Cl
was weaker than that due to the adducts of cisplatin.
Sequence analysis of the termination sites produced by
cisplatin and [PtCl(dien)]Cl conﬁrmed a strong preference
of their DNA binding to guanine residues (Figure 5B).
Interestingly, intense platination by both cisplatin and
[PtCl(dien)]Cl occurred at three consecutive G residues
(sites 38–40 and 120–122) on the scissile strand of the
161-bp fragment. These sites are immediately downstream
of the cleavage sites 37 and 119, respectively at which top1
normally cleaves DNA both in the presence and absence
of CPT. Other residues in the close proximity of the cleav-
age site of top1 on the scissile strand was that at the
guanine residue 93, i.e. immediately downstream of the
cleavage site 92. This G residue (93) was, however, metal-
lated only by cisplatin (Figure 5). Also interestingly,
the single A residue 98 immediately downstream of the
cleavage site 97 was also metallated, but mainly by
[PtCl(dien)]Cl (Figure 5). Other platinated sites in the
161-bp fragment modiﬁed by cisplatin or [PtCl(dien)]Cl
in the immediate neighborhood of the cleavage sites of
top1 on the scissile strand were not observed (Figure 5).
Top1-mediated cleavage of the 30-bp oligonucleotide
duplex
The inﬂuence of major adducts of cisplatin and
[PtCl(dien)]Cl on the activity of eukaryotic top1 was
Figure 2. Inhibition of top1-mediated relaxation of negatively supercoiled pSP73KB plasmid by cisplatin or [PtCl(dien)]Cl adducts in the absence or
presence of CPT analyzed by agarose gel electrophoresis. (A and B) Electrophoretograms of nonmodiﬁed plasmid (top gels in panels A and B) and
plasmid modiﬁed by cisplatin (A) or [PtCl(dien)]Cl (B) to rb=0.02 (bottom gels in panels A and B) were treated with top1 in the absence or presence
of 100mM CPT. Sets of lanes in panels A and B represent increasing reaction times in minutes before termination of the reaction by 0.5% SDS;
samples were then mixed with loading buﬀer and electrophorezed. (C–E) Plots of plasmid DNA relaxation mediated by top1 (see panels A and B).
At the indicated times, aliquots were removed, the reaction was terminated with 0.5% SDS, electrophoresed and the percentage of supercoiled form
of DNA was determined by densitometry. Filled square and open square correspond to unplatinated supercoiled plasmid treated with top1 in the
absence and presence of 100mM CPT, respectively. Filled circle and open circle correspond to supercoiled plasmid modiﬁed by cisplatin to rb=0.02
(C) or [PtCl(dien)]Cl to rb=0.02 (D) and 0.04 (E) treated with top1 in the absence and presence of CPT, respectively.
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containing a unique top1 cleavage site (22,32,33)
(Figure 6A). Top1 cleaves one strand of double-helical
DNA between T and G(+1)G(+2) bases in the
50-CTTG(+1)G(+2)A- sequence derived from the oligo-
nucleotide used for determination of the crystal structure
of human top1 bound to this DNA substrate (34,35)
(Figure 6B and C). The presence of two adjacent guanine
bases made it possible to prepare on the scissile strand at
the +1 and +2 positions downstream from the top1 scis-
sile bond the most frequent adduct of cisplatin, 1,2-GG
intrastrand crosslink, which is believed to be responsible
for its antitumor activity. It seems interesting to test
whether extensive distortions induced in DNA by forma-
tion of the 1,2-GG intrastrand crosslink within top1 bind-
ing site aﬀect activity of top1. Indeed, cleavage of the
duplex by top1 is completely inhibited by formation
of cisplatin adduct (Figure 6B, lane 4) and no cleavage
products are observed even in the presence of CPT
(Figure 6B, lane 6). This result suggests that the presence
of 1,2-GG intrastrand crosslink of cisplatin interferes with
top1 recognition of its DNA binding site and formation of
top1–DNA cleavable complex.
In order to discriminate whether the cleavage activity of
top1 is inhibited by distortion of the DNA structure
caused by formation of the 1,2-GG intrastrand crosslink
per se or by chemical modiﬁcation of the guanine bases
adjacent to the cleavage site by the platinum complex, we
also prepared substrates containing single, site-speciﬁc
adduct of monodentate [PtCl(dien)]Cl which preferentially
forms monofunctional adducts at N7 of guanine residues.
This type of adducts has been shown to cause markedly
less extensive distortions in DNA structure compared to
1,2-intrastrand crosslink of bidentate cisplatin (24,36).
The upper (scissile) strand of the substrate contains two
consecutive guanines, which are all preferential binding
sites of [PtCl(dien)]Cl (37). To ensure that exclusively
only one guanine at the +1 or +2 position of the 30-bp
duplex (Figure 6A) is modiﬁed by [PtCl(dien)]Cl, either
guanine at +1 or +2 position was replaced by 7-deaza-
guanine (7-deazaG). The 7-deazaG is an isosteric analog
of native guanine, in which the aromatic N7 atom is
replaced with a C-H and which accurately mimics the
properties of the natural base. As the guanine N7 is the
site where platinum complexes preferentially react in
DNA, 7-deazaG is incapable of forming platinum adducts
(38). Thus, 7-deazaG makes it possible to prepare a single
monofunctional adduct of [PtCl(dien)]Cl at the guanine
residue at either +1 or +2 position. The results shown
in Figure 6C, lanes 3, 5, 9, 11) demonstrate that replace-
ment of guanines by 7-deaza-dG in nonmodiﬁed substrate
has no eﬀect on the cleavage activity of top1. On the other
hand, modiﬁcation of guanine at either +1 or +2 posi-
tion by [PtCl(dien)]Cl completely inhibits cleavage of the
Figure 3. Eﬀect of DNA modiﬁcation by cisplatin (A, lanes cisPt) or [PtCl(dien)]Cl (B, lanes dienPt) on top1-mediated cleavage in the presence of
CPT. A 161bp 30-end labeled DNA fragment modiﬁed by cisplatin or [PtCl(dien)]Cl at rb=0.00625, 0.0125, 0.025, 0.05, 0.1 and 0.2 was treated with
top1 in the presence of 5mM CPT. After 30min, reactions were terminated by addition of SDS and the sample was split into two parts. One half of
the sample was analyzed immediately (gels on the left of each panel) by PAA electrophoresis under denaturing conditions and the other half (gels on
the right of each panel) was ﬁrst incubated with NaCN to remove platinum adducts and only then electrophoresed. Lanes control, nonmodiﬁed
DNA treated with top1 in the presence of 5mM CPT; lanes G correspond to Maxam–Gilbert G ladder. DNA sequences of the ﬁve major cleavage
sites mediated by top1 in the presence of CPT are shown on the right of (B). The arrow indicates the position of the DNA single-strand breaks and
guanines as potential preferential binding sites of cisplatin and [PtCl(dien)]Cl are highlighted as bold letters.
Nucleic Acids Research, 2009,Vol.37, No. 16 5437substrate by top1 and no cleavage is observed even in
the presence of CPT. Thus, these results (Figure 6C) are
identical to those obtained with cisplatin (Figure 6B) and
demonstrate that top1 is very sensitive to the modiﬁcation
of bases in a close proximity of its cleavage site by plati-
num complexes.
DISCUSSION
Chemical agents able to interfere with DNA topoisom-
erases are widespread in nature, and some of them have
clinical eﬃcacy as antitumor or antibacterial drugs. Drugs
which have as a target DNA topoisomerases can be
divided into two categories: poisons and suppressors
(39). Classical topoisomerase ‘poisons’ stimulate cleavage
in a sequence-selective manner, yielding drug-speciﬁc
cleavage intensity pattern. Top1 ‘suppressors’ inhibit the
ability of top1 to cleave the phosphodiester backbone of
supercoiled DNA by preventing or reversing top1–DNA
complex formation (40). The suppressors may modify
DNA chemically or even alter DNA conformation, pre-
venting top1 binding to the top1 cleavage sites (41,42).
Our results indicate that the presence of platinum
adducts in the substrate DNA inhibits top1 action in a
manner dependent on the level of DNA platination. As
determined by DNA relaxation assay, the yield of top1
catalysis decreases as a consequence of global modiﬁca-
tion of plasmid by antitumor cisplatin considerably more
than due to modiﬁcation by [PtCl(dien)]Cl (Figure 2).
Figure 5. (A) Autoradiograms of 6% polyacrylamide/8M urea sequen-
cing gel showing inhibition of DNA synthesis by VentR(exo ) DNA
polymerase on the 161-bp PvuII/HindIII fragment of pBluescript
SK( ) phagemid and subsequently modiﬁed by cisplatin or
[PtCl(dien)]Cl. The gels contained the linear ampliﬁcation products of
control, nonplatinated DNA, and DNA treated with cisplatin or
[PtCl(dien)]Cl at rb=0.005 or 0.008. Lanes are as follows: (control)
unmodiﬁed template; lanes, cisPt1 and dienPt1, DNA modiﬁed by cis-
platin or [PtCl(dien)]Cl, respectively, at rb=0.005; lanes, cisPt2 and
dienPt2, DNA modiﬁed by cisplatin or [PtCl(dien)]Cl, respectively, at
rb=0.008; lanes C, G, T, A, chain-terminated marker DNAs (note that
these dideoxy sequencing lanes give the sequence complementary to the
template strand). The numbers correspond to the nucleotide sequence
numbering of part B. Left panel, mapping of the Pt adducts formed on
the top strand of the 161-bp fragment; right panel, mapping of the Pt
adducts formed on the bottom strand of the 161-bp fragment. (B)
Schematic diagram showing a portion of the sequence used to monitor
inhibition of DNA synthesis on the template containing adducts of
cisplatin or [PtCl(dien)]Cl. Solid circles indicate major stop signals
from part A, lane cisPt2, open circles indicate major stop signals
from part A, lane dienPt2. The numbering of the nucleotides in
this scheme corresponds to the cleavage sites of top1 (Figure 4).
Nucleotides 37, 70, 92, 97 and 119 correspond respectively to nucleo-
tides 569, 602, 624, 629 and 741 on the pBluescript SK( ) phagemid
nucleotide sequence map.
Figure 4. The dependence of the DNA cleavage of the 161-bp PvuII/
HindIII fragment of pBluescript SK(-) phagemid mediated by top1
in the presence of CPT on the level of DNA modiﬁcation by cisplatin
(A) and [PtCl(dien)]Cl (B). The relative cleavage was calculated as a
ratio of the intensities of the bands corresponding to the ﬁve main
cleavage sites (Figure 3) induced by top1 in unplatinated and platinated
DNA in the presence of CPT after removal of the platinum adducts by
treatment with NaCN.
5438 Nucleic Acids Research, 2009, Vol. 37,No. 16Alkaloid CPT is top1 poison which binds neither to DNA
nor top1 alone. It does bind, however, to DNA–top1 com-
plexes forming stabilized cleavage complexes, thereby
inhibiting the resealing of the cleaved form of top1–
DNA complexes (43). Interestingly, when CPT is present
in the samples containing DNA modiﬁed by the platinum
complexes, resulting inhibitory eﬀects on top1 activity are
markedly enhanced and additive or more than additive
depending on the level of DNA platination (Figure 2).
Thus, the results of DNA relaxation experiments
(Figure 2) support the hypothesis that the biological
(toxic) eﬀects of cisplatin are due, in part, to inhibition
of top1 catalytic activity, which is even more pronounced
in the presence of CPTs.
Top1 inhibitors aﬀect cleavage in a sequence-selective
manner (42,44,45). In order to investigate whether
platinum adducts suppress top1 catalytic activity in a
sequence-selective manner, we examined the DNA
sequence locations of preferred cleavage sites in the
161-bp PvuII/HindIII fragment of pBluescript SK( ) pha-
gemid DNA modiﬁed by cisplatin or [PtCl(dien)]Cl in
presence of CPT (Figures 3 and 4). This fragment contains
several sequences corresponding to high aﬃnity top1
cleavage sites in the scissile strand with thymine and
guanine (adenine) residues at the  1 and +1 positions
(immediately upstream or downstream of the cleavage
site), respectively (31). Moreover, CPT is known to pre-
ferentially enhance DNA breakage at sites with a guanine
base at the +1 position on the scissile strand, immediately
downstream of the cleavage site (46). Intriguingly, the
results show that the eﬀects of platinum adducts on the
catalytic activity of top1 in the presence of CPT may
fundamentally diﬀer depending not only on the sequence
context, but also on the bidentate or monodentate char-
acter of the platinum complex.
Inspection of the cleaved sequences reveals that the sites
at which DNA cleavage is strongly suppressed (the sites 37
and 119 of the 161-bp fragment) occur in the sequences
containing three consecutive guanines on the scissile
strand, immediately downstream of the cleavage site (at
positions +1, +2 and +3) at which top1 normally cleaves
DNA both in the presence and absence of CPT. Three
guanines in a row represent highly attractive binding site
for both cisplatin and [PtCl(dien)]Cl (37,47,48) as also
conﬁrmed by the results of our replication mapping
experiments (Figure 5). While cisplatin can readily form
its major 1,2-GG intrastrand crosslink in this sequence,
the three guanines in this sequence represent even three
high aﬃnity binding sites for monodentate [PtCl(dien)]Cl
which forms monofunctional adducts preferentially at
guanine residues and in a lesser extent also at adenine
residues (37). Thus, the platinum adducts formed at the
top1 cleavage sites at the 37 and 119 positions of the
161-bp fragment (Figures 3 and 4) inhibit the ability
of top1 to cleave the phosphodiester backbone of
DNA apparently by preventing top1–DNA or ternary
top1–CPT–DNA complex formation, i.e. exhibit features
typical for top1 suppressors.
It is interesting that DNA cleavage is strongly sup-
pressed at these sequences by the adducts of both cisplatin
and monodentate [PtCl(dien)]Cl although the eﬀect of
Figure 6. Inhibition of top1 cleavage by single, site-speciﬁc 1,2-GG
intrastrand crosslink of cisplatin at the +1 and +2 positions or by
single, site-speciﬁc monofunctional adduct of [PtCl(dien)]Cl at the +1
or +2 position of the scissile strand of an 30-bp oligodeoxyribonucleo-
tide duplex containing a single top1 cleavage site. (A) DNA substrate
for top1 cleavage. A modiﬁed Tetrahymena hexadecameric rDNA
sequence with a strong top1 cleavage site indicated by the arrow
(22,23) was labeled with [a-
32P]-dATP (
 A) at the 30-end of the scissile
(upper) strand as described under Materials and Methods section.
Cleavage at the normal site (arrow) gives rise to an 18-mer product
as indicated. Platinated guanines (highlighted as bold Gs) and other
guanine residues are deﬁned using the numbering shown at the bot-
tom relative to the top1 cleavage site. B and C. Oligonucleotide
duplexes ( 5nM) with indicated platinum adducts of cisplatin (B)o r
[PtCl(dien)]Cl (C) at the +1 and/or +2 positions relative to the top1
cleavage site were incubated with  60pM top1 in the absence or pres-
ence of 10mM CPT and used as follows: lanes 1 and 7, unplatinated
duplex in absence of top1; lanes 2 and 8, duplex containing 1,2-GG
intrastrand crosslink of cisplatin or monofunctional adduct of
[PtCl(dien)]Cl in absence of top1; lanes 3 and 9, unplatinated duplex
+ top1; lanes 4 and 10, duplex containing 1,2-GG intrastrand crosslink
of cisplatin or monofunctional adduct of [PtCl(dien)]Cl+top1; lanes 5
and 11, unplatinated duplex+top1+10mM CPT; lanes 6 and 12,
duplex containing 1,2-GG intrastrand crosslink of cisplatin or mono-
functional adduct of [PtCl(dien)]Cl+top1+10mM CPT; lanes M1,
single-stranded 17-mer marker; lanes M2, mixture of single-stranded
18- and 19-mer markers. Reactions were performed at 208C for 30min,
stopped with 0.5% SDS and loaded on 24% PAA denaturing gel.
Nucleic Acids Research, 2009,Vol.37, No. 16 5439the [PtCl(dien)]Cl adducts is slightly less pronounced. This
observation may be interpreted to mean that severe con-
formational alterations induced in DNA by the 1,2-GG
intrastrand crosslink of cisplatin, which is the major
adduct formed in DNA by this metallodrug, are not impli-
citly critical for suppression of DNA cleavage by top1 in
the presence of CPT. Also interestingly, DNA cleavage at
some sequences containing only one guanine residue in the
immediate proximity of the cleavage site on the scissile
strand (at the 70 and 92 positions, Figure 4) is not sup-
pressed or is suppressed only slightly if the fragment was
globally modiﬁed by cisplatin. The observation that DNA
cleavage at the site 70 is almost unaﬀected by the global
modiﬁcation of the fragment by cisplatin or [PtCl(dien)]Cl
is apparently associated with the fact that the single G
immediately downstream of the cleavage site 70 was not
metallated by these complexes (Figure 5). DNA cleavage
was suppressed at the site 92 only slightly even when the
neighboring single G at the 93 site was metallated by cis-
platin. Similarly, DNA cleavage was also suppressed only
slightly at the site 97 when the neighboring single A at the
98 site was metallated by[PtCl(dien)]Cl. Thus, rather a
multiple metallation of the short nucleotide sequences
on the scissile strand, immediately downstream of the
cleavage site and/or platination of the residues at the
+2 and/or +3 position appears to impede the cleavage
by top1 in the presence of CPT.
In order to shed light on the eﬀect of platination of
guanine residues at the +1 and +2 positions on the scis-
sile strand, we also examined cleavage by top1 in the
absence or presence of CPT of the 30-bp duplex
(Figure 6A), which contains a single high-aﬃnity top1
cleavage site on the scissile strand [between thymine
( 1) and two guanines (+1 and +2) (Figure 6A)]. The
results of these experiments (Figure 6B and C) conﬁrm
that even a single platination of the guanine residue by
[PtCl(dien)]Cl at the +2 position eﬀectively suppress
DNA cleavage by top1 in both the presence or absence
of CPT. This results further supports the view that plati-
nation of the guanine residue not immediately down-
stream of the cleavage site at which top1 normally
cleaves is important in the mechanism of suppression of
the catalytic activity of top1.
The mechanism of enhanced cleavage of DNA in the
presence of CPT involves stabilization of the normally
transient cleavable DNA–top1 complex and formation
of an enzyme–drug–DNA ternary cleavable complex
(49). It has been suggested (50) that this ternary complex
is stabilized not only by interactions between CPT and
top1, but also by interaction between intercalated CPT
and a ﬂipped base at the +1 position. Therefore, it
seems reasonable to speculate that a multiple platination
of bases on the scissile strand, immediately downstream of
the cleavage site and/or platination of the guanine residues
at the +2 and/or +3 position may impede interaction
between intercalated CPT and a ﬂipped base at the +1
position by hampering either CPT intercalation and/or
ﬂipping the guanine base at the +1 position. Other experi-
ments are needed to support this hypothesis.
An intriguing ﬁnding is that DNA cleavage by top1
in the presence of CPT at the sites corresponding to the
92 and 97 positions was notably enhanced in particular at
lower levels of global modiﬁcation of the 161-bp fragment
by [PtCl(dien)]Cl or cisplatin, respectively (Figure 4).
This enhancement was only observed if no residues in
the immediate proximity of the cleavage sites 92 or 97
were platinated. Hence, a plausible explanation of this
enhancement of DNA cleavage by top1 may consist in
the inability of top1 to bind to its cleavage sites 37 and
119 due to multiple metallation by cisplatin or
[PtCl(dien)]Cl immediately downstream of these cleavage
sites. Thus, more molecules of top1 could be available for
cleavage at the sites where top1 normally cleaves and
where platination does not interfere in the immediate
vicinity of these cleavage sites. In other words, enhance-
ment of DNA cleavage by top1 in the presence of CPT at
the sites corresponding to the 92 and 97 positions
(Figure 4) was not due to platinum-induced structural
change in DNA, but rather due to displacement of the
top1/CPT complex from platinum–DNA binding sites,
thus increasing its concentration elsewhere. Similar phe-
nomenon was observed earlier in DNaseI footprinting
experiments (51,52). This hypothesis is also corroborated
by the fact that the reaction, in which top1-mediated
cleavage of the 161-bp DNA fragment was examined
(Figure 3), contained one molecule of top1 per more
than 200 top1 cleavage sites in the sample of the 161-bp
fragment. On the other hand, it should be pointed out that
this ‘displacement’ mechanism may not necessarily act in
an in vivo situation when the level of DNA platination in
cells treated with platinum complexes is pronouncedly
lower.
In this respect, an earlier study of Schellens and cow-
orkers (18) dealing with the eﬀect of DNA adducts of
cisplatin on poisoning of top1 by CPT deserves further
discussion. This study has demonstrated that single, site-
speciﬁc 1,3-GTG intrastrand crosslink of cisplatin formed
in the 24-bp duplex produces two cleavage sites of top1 on
the platinated strand in the presence of CPT. One cleavage
site, between C and T residues of the platinated strand,
was separated by one nucleotide downstream of the 30
guanine involved in the 1,3-GTG intrastrand crosslink.
DNA cleavage was enhanced at this site as a consequence
of the presence of the 1,3-intrastrand crosslink. The other
top1 cleavage site (not observed in the unplatinated
duplex) occurred in the same strand between G and C
residues in the immediate proximity of the 30 G residue
of the crosslink. These results have been interpreted to
mean that the 1,3-GTG intrastrand crosslink of cisplatin
acts as a top1 poison (18). Nevertheless, the 1,3-GTG
intrastrand crosslink of cisplatin examined in the work
of Schellens and coworkers (18) only represents a minor
DNA adduct of cisplatin which distorts DNA in a way
distinctly diﬀerent from that by which DNA is distorted
by the major adducts of cisplatin, such as 1,2-GG or AG
intrastrand crosslink (4,53). In addition, the sequence of
the 24-bp oligonucleotide used in their study contained no
canonical (preferential) cleavage site of top1 so that a
direct comparison with the results of the present study
cannot be straightforward.
Top1 breaks double-helical DNA at sites that occur, on
the average, more frequently than 1 per 10 bases (44).
5440 Nucleic Acids Research, 2009, Vol. 37,No. 16Even if one considers only the strong sites, which occur on
the average every 30 to 35 bases on one strand, a random
sequence of duplex DNA will contain a site every 1 to 2
turns of the helix. Thus, it cannot be excluded that at the
levels of platination of DNA in tumor cells of patients
treated with antitumor cisplatin this metallodrug may
also bind at or close to the DNA cleavage sites of top1.
It might be so also because canonical cleavage sites of top1
contain a number of high aﬃnity binding sites for cisplatin
and other antitumor platinum drugs. It seems therefore
quite reasonable to suggest that mechanisms underlying
antitumor eﬀects of cisplatin and perhaps of other plati-
num drugs may also involve eﬀects of these metallodrugs
on top1 catalytic activity.
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